TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
IKT

Inhibikase Therapeutics Inc

Healthcare · Biotechnology

2.10$ -1.9% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow IKT
Line item 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-3.1% -6.1% 17.7% -30.1% -161.7% -461.1% -14,056.3% -6,942.4% – –
– – – – – 0.0% 5.4% 68.1% – –
32.1% 14.6% 15.9% 128.0% 82.1% 49.4% 371.1% 192.0% – –
31.9% 16.6% 33.4% 192.5% 312.6% 72.7% – – – –
20.0% -1.6% 37.5% 145.3% -66.5% -56.9% 138.7% 90.1% – –
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 197.1% 5.5% – –
9.0% 4.2% 2.2% – – – -12,966.4% 4,474.7% – –
– – – – – 2.5% – – – –
– – – – – -2.5% – – – –
-2.5% 6.4% -0.7% -2.0% 39.1% -1.4% -201.6% 0.0% – –
-2.5% 6.4% -10.9% -2.0% 2,156.8% 1,325.3% -165.9% 3,226.5% – –
-5.5% 0.2% 9.0% -32.2% 1,995.1% 864.2% -27,188.6% 758.8% – –
-3.1% -6.1% 17.7% -30.1% -161.7% -461.1% -14,253.4% -6,947.9% – –

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?